2009 Form 990-PF - Bill & Melinda Gates Foundation

BILL & MELINDA GATES FOUNDATION 56-2618866
FORM 990PF, PART XV - GRANTS AND CONTRIBUTIONS PAID DURING THE YEAR
RELATIONSHIP TO SUBSTANTIAL CONTRIBUTOR
AND
ATTACHMENT 18 (CONT'D)
RECIPIENT NAME AND ADDRESS FOUNDATION STATUS OF RECIPIENT PURPOSE OF GRANT OR CONTRIBUTION AMOUNT
FRAUNHOFER USA INC NONE FOR PRE-CLINICAL AND PHASE 1 DEVELOPMENT OF
2,433,446.
9 INNOVATION WAY 509(A)(2)
SUITE 200
NEWARK, DE 19711
TRANSMISSION BLOCKING VACCINES
FRED HUTCHINSON CANCER RESEARCH CTR NONE TO IMPROVE HIV VACCINES THAT CAN CONTROL THE
6,778,393.
1100 FAIRVIEW AVE N 509(A)(1)
J6-500
SEATTLE, WA 981091024
AIDS EPIDEMIC
FRED HUTCHINSON CANCER RESEARCH CTR NONE TO ESTABLISH A VACCINE IMMUNOLOGY STATISTICAL
1,872,269.
1100 FAIRVIEW AVE N 509(A)(1)
J6-500
SEATTLE, WA 981091024
CENTER (VISC) TO PROVIDE STATISTICAL AND DATA
MANAGEMENT SUPPORT TO THE VACCINE DISCOVERY
FRED HUTCHINSON CANCER RESEARCH CTR NONE TO ELUCIDATE THE INNATE AND ADAPTIVE IMMUNE
2,671,877.
1100 FAIRVIEW AVE N 509(A)(1)
J6-500
SEATTLE, WA 981091024
CENTERS
RESPONSES THAT CAN PROTECT AGAINST HIV-1
INFECTION AT ALL AGES
FRED HUTCHINSON CANCER RESEARCH CTR NONE GERALD R. SMITH OF THE FRED HUTCHINSON CANCER
100,000.
1100 FAIRVIEW AVE N 509(A)(1)
J6-500
SEATTLE, WA 981091024
RESEARCH CENTER IN THE U.S. SEEKS TO IDENTIFY
INHIBITORS OF A BACTERIAL DNA REPAIR ENZYME
THAT ALLOWS TUBERCULOSIS TO MUTATE.
IDENTIFYING THESE INHIBITORS COULD LEAD TO
THERAPIES THAT KILL BACTERIA AND LIMIT DRUG
RESISTANCE.
FREEDOM FROM HUNGER NONE TO PROVIDE HEALTH PROTECTION SERVICES TO
1,750,716.
1644 DAVINCI 509(A)(1)
DAVIS, CA 95616
FOR PUBLIC DISCLOSURE
88 OF 519
IMPROVE THE COMMERCIAL VIABILITY OF
MICROFINANCE FOR THE VERY POOR IN AFRICA,
ASIA, AND LATIN AMERICA
ATTACHMENT 18